Younis Irfan, Sarwar Shahid, Butt Zeeshan, Tanveer Sheharyar, Qaadir Adnan, Jadoon Nauman Arif
Nawaz Sharif Medical College Gujrat, Pakistan.
King Edward Medical University Lahore, Pakistan.
Ann Hepatol. 2015 May-Jun;14(3):354-60.
Hepatopulmonary syndrome (HPS) is a complication of advanced liver disease. The impact of HPS on survival is not clearly understood.
A prospective study was carried out at Department of Medicine, King Edward Medical University Lahore from June 2011 to May 2012. Patients with cirrhosis of liver were evaluated for presence of HPS with arterial blood gas analysis and saline bubble echocardiography. All patients were followed for 6 months for complications and mortality. Cox regression analysis was done to evaluate role of HPS on patient survival.
110 patients were included in the study. Twenty-nine patients (26%) had HPS. MELD score was significantly higher (p < 0.01) in patients with HPS (18.93 ± 3.51) as compared to that in patients without HPS (13.52 ± 3.3). Twenty two (75.9%) patients of Child class C, 5 (17.2%) patients of Child class B and 2 (6.9%) patients of Child class A had HPS (P 0.03). The clinical variables associated with presence of HPS were spider nevi, digital clubbing, dyspnea, and platypnea. HPS significantly increased mortality during six month follow up period (HR: 2.47, 95% CI: 1.10- 5.55). Child-Pugh and MELD scores were also associated with increased mortality. HPS was no longer associated with mortality when adjustment was done for age, gender, Child-Pugh, and MELD scores (HR: 0.44, 95% CI: 0.14-1.41). Both the Child-Pugh and MELD scores remained significantly associated with mortality in the multivariate survival analysis.
HPS indicates advanced liver disease. HPS does not affect mortality when adjusted for severity of cirrhosis.
肝肺综合征(HPS)是晚期肝病的一种并发症。HPS对生存率的影响尚不清楚。
2011年6月至2012年5月在拉合尔爱德华国王医科大学医学系进行了一项前瞻性研究。通过动脉血气分析和生理盐水气泡超声心动图对肝硬化患者进行HPS评估。所有患者随访6个月,观察并发症和死亡率。采用Cox回归分析评估HPS对患者生存的作用。
110例患者纳入研究。29例(26%)患者患有HPS。与无HPS患者(13.52±3.3)相比,HPS患者的终末期肝病模型(MELD)评分显著更高(p<0.01)(18.93±3.51)。Child C级患者中有22例(75.9%)、Child B级患者中有5例(17.2%)、Child A级患者中有2例(6.9%)患有HPS(P 0.03)。与HPS存在相关的临床变量有蜘蛛痣、杵状指、呼吸困难和平卧呼吸。HPS在6个月随访期内显著增加死亡率(风险比:2.47,95%置信区间:1.10 - 5.55)。Child-Pugh评分和MELD评分也与死亡率增加相关。在对年龄、性别、Child-Pugh评分和MELD评分进行校正后,HPS与死亡率不再相关(风险比:0.44,95%置信区间:0.14 - 1.41)。在多因素生存分析中,Child-Pugh评分和MELD评分均仍与死亡率显著相关。
HPS提示晚期肝病。校正肝硬化严重程度后,HPS不影响死亡率。